KYMR
USDKymera Therapeutics Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$55.800
Máximo
$61.580
Mínimo
$55.660
Volume
0.77M
Fundamentos da empresa
Capitalização de mercado
4.3B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.75M
Bolsa de valores
NGM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics with a Buy and raises the price target from $59 to $75.
Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81
Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics with a Outperform rating and announces Price Target of $81.
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.